A total of 859 patients from seven randomized controlled trials were included in the meta-analysis. Similar pooled outcome was demonstrated in terms of oral PPI versus intravenous PPI in the rate of recurrent bleeding within a 30-day of follow-up period (risk ratio = 0.90; 95%CI: 0.58, 1.39; P = 0.62; I2 = 0%). In terms of the rate of mortality, both oral and intravenous PPIs showed similar outcomes, and the pooled risk ratio was 0.88 (95%CI: 0.29, 2.71; P = 0.82; I2 = 0%). Likewise, no significant difference was detected in blood transfusion and hospital stay, and the pooled mean differences were -0.14 (95%CI: -0.39, 0.12; P = 0.29; I2 = 32%) and -0.60 (95%CI: -1.42, 0.23; P = 0.16; I2 = 79%) respectively.
A total of 859 patients from seven randomized controlled trials were included in the meta-analysis. Similar pooled outcome was demonstrated in terms of oral PPI versus intravenous PPI in the rate of recurrent bleeding within a 30-day of follow-up period (risk ratio = 0.90; 95%CI: 0.58, 1.39; P = 0.62; I2 = 0%). In terms of the rate of mortality, both oral and intravenous PPIs showed similar outcomes, and the pooled risk ratio was 0.88 (95%CI: 0.29, 2.71; P = 0.82; I2 = 0%). Likewise, no significant difference was detected in blood transfusion and hospital stay, and the pooled mean differences were -0.14 (95%CI: -0.39, 0.12; P = 0.29; I2 = 32%) and -0.60 (95%CI: -1.42, 0.23; P = 0.16; I2 = 79%) respectively.
การแปล กรุณารอสักครู่..
